Condition: Common Warts · Common Warts (Verruca Vulgaris) · Human Papilloma Virus (HPV) · Sponsor: Verrica Pharmaceuticals Inc.
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
This description comes directly from the study's public registry record.
Project Manager · 484-453-3295 · 17338-COVE2@allucent.com
Always discuss trial participation with your own doctor first.
| Florida Center for Dermatology, P.A. | Saint Augustine, Florida, United States | Recruiting |
| The Indiana Clinical Trials Center, PC | Plainfield, Indiana, United States | Recruiting |
| Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein | Hunt Valley, Maryland, United States | Recruiting |
| Tennessee Clinical Research Center, Inc. | Nashville, Tennessee, United States | Recruiting |
| The University of Texas Health Science Center at Houston | Houston, Texas, United States | Not Yet Recruiting |
| Texas Dermatology and Laser Specialists | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07246590